Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

French medical professionals strike in droves:

This article was originally published in Clinica

Executive Summary

The French medical professionals' protest continues. On March 10, there was an all-out strike on March 10 with 50,000 healthcare professionals on the streets of Paris demanding better conditions. The GPs among them were demanding a 15% increase in their consultation fees, to Euro20 ($17.40), and a 46% increase in home visit fees to Euro30 (see Clinica No 997, p 3). On March 12, there was another demonstration in Paris, this time in protest at the consequences of the recently introduced 35-hour week. Healthcare professionals are demanding additional resources and staff to cope with the impact of this ruling. The unrest is snowballing at a critical time: the government is preparing for forthcoming elections. But it will be a tall order for any government to accede to the GPs demands for an increase in their consultation fees: it would cost the social security some Euro250 million a year.

You may also be interested in...



Prestige Expands UK Eye Care Range In Response To Consumer Demand

A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.

Who’s Hired? Hikma Recruits New US Generics President

A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.

Organon And Henlius Complete Phase III For Denosumab

Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT065820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel